Question 1

What is Descovy?

Accepted Answer

Descovy is a combination medicine that contains emtricitabine and tenofovir alafenamide. These two active ingredients belong to a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs).

The medication works by interfering with the ability of the virus to replicate within the body. It is used to manage human immunodeficiency virus (HIV) or to reduce the risk of acquiring the virus.

Question 2

What is Descovy used for?

Accepted Answer

Descovy is used to treat HIV-1 infection and for HIV-1 pre-exposure prophylaxis .

Question 3

How does Descovy work?

Accepted Answer

Mechanism of Action

Descovy is a combination of two active ingredients: emtricitabine and tenofovir alafenamide. Both medications belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

To multiply and spread throughout the body, HIV must convert its genetic material (RNA) into DNA. The virus uses a protein called reverse transcriptase to complete this process. The ingredients in Descovy act as decoys that mimic the natural building blocks the virus needs. When the virus attempts to use these decoys to build its DNA, the process is interrupted, and the virus is unable to create functional copies of itself.

How It Functions in the Body

The medication serves different roles depending on whether it is used for treatment or prevention:

Treatment of HIV: In individuals already living with HIV, Descovy is used alongside other antiretroviral medications. By stopping the virus from replicating, it reduces the viral load (the amount of HIV in the blood). This allows the immune system, specifically CD4 cells, to recover and better protect the body from other infections.

Prevention of HIV (PrEP): When used as pre-exposure prophylaxis (PrEP), the medication is taken to maintain a consistent level of the drug in the bloodstream and tissues. If a person is exposed to HIV, the drug is already present to block the virus from replicating, which prevents it from establishing a permanent infection in the body.

By interfering with the life cycle of the virus, the medication helps manage the progression of the infection or provides a barrier against new infections.

Question 4

What are the active ingredients in Descovy?

Accepted Answer

The active ingredients in Descovy are tenofovir alafenamide and emtricitabine .

Question 5

What are the side effects of Descovy?

Accepted Answer

Common side effects of Descovy may include:

Nausea

Diarrhea

Headache

and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Descovy?

Accepted Answer

Descovy belongs to the NRTI combination drug class.

Question 7

What is the dosage of Descovy and how do I take it?

Accepted Answer

How to Take This Medication

Descovy is a tablet taken by mouth. It is usually prescribed to be taken once every day. You may take this medication with or without food. For the best results, try to take your dose at the same time each day to maintain a consistent level of the medicine in your body.

If you are taking Descovy for HIV-1 treatment, it must be used along with other antiretroviral medications as prescribed by your healthcare provider. If you are taking it for pre-exposure prophylaxis (PrEP), it is essential to take it every day to ensure it works effectively to reduce the risk of infection.

Missed Doses

If you miss a dose of Descovy, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time to make up for a missed one.

It is important not to run out of this medication. Ensure you refill your prescription before your supply is gone. Skipping doses or stopping the medication abruptly can increase the risk of the virus becoming resistant to treatment or reduce the effectiveness of PrEP.

General Instructions

Do not change your dose or stop taking this medication without consulting your healthcare provider. If you have hepatitis B, stopping Descovy may cause your condition to worsen. Your doctor will monitor your health closely if you need to stop treatment.

Question 8

Is Descovy safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited research on the use of Descovy during pregnancy. If you are pregnant or planning to become pregnant, talk to your healthcare provider about the potential risks and benefits. For those treating HIV, maintaining an undetectable viral load is essential for the health of the parent and to prevent transmission of the virus to the baby.

It is important to note that Descovy is not approved for HIV prevention (PrEP) in people assigned female at birth who are at risk of HIV through vaginal sex, as its effectiveness has not been studied in this population.

A pregnancy registry exists to monitor outcomes for people who take antiretroviral medications while pregnant. Healthcare providers use this registry to track the safety of the medication for both the parent and the child.

Breastfeeding

Health authorities generally recommend that people with HIV do not breastfeed to prevent the transmission of HIV to the baby through breast milk. Furthermore, the active ingredients in Descovy, emtricitabine and tenofovir, pass into breast milk. The potential effects of these medications on a nursing infant are not fully known.

Question 9

What forms and strengths does Descovy come in?

Accepted Answer

Descovy is supplied as a film-coated tablet for oral administration. It is a fixed-dose combination medication, meaning each tablet contains two different active ingredients.

Oral Tablet: These tablets are swallowed whole and are available in different shapes and colors to identify the specific formulation.

Question 10

What is the FDA approval status of Descovy?

Accepted Answer

The U.S. Food and Drug Administration (FDA) first approved Descovy in 2016. It is currently approved for two primary uses:

HIV-1 Treatment: Used in combination with other antiretroviral agents to treat HIV-1 infection in adults and pediatric patients weighing at least 35 kg. It is also approved for certain pediatric patients weighing at least 14 kg to less than 35 kg in specific treatment combinations.

HIV-1 Pre-Exposure Prophylaxis (PrEP): Used to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing at least 35 kg. However, it is not indicated for individuals at risk through receptive vaginal sex because its effectiveness in this population has not been evaluated.

Descovy carries a boxed warning, the FDA’s most serious type of warning, for the following risks:

Post-Treatment Acute Exacerbation of Hepatitis B

Patients with both HIV-1 and hepatitis B virus (HBV) infection may experience severe, acute worsening of hepatitis B after they stop taking Descovy. Healthcare providers typically monitor liver function closely for several months in patients who discontinue the medication and have a history of HBV.

Risk of Drug Resistance with PrEP Use

Descovy for PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately before starting the medication and at least every three months while taking it. Using the drug for PrEP while having an undiagnosed HIV-1 infection can lead to the development of drug-resistant HIV-1 strains.

There is currently no FDA-approved generic version of Descovy available in the United States. The medication remains under patent protection and regulatory exclusivity, which prevents generic manufacturers from marketing the drug at this time.

Question 11

What should I know about Descovy and cost?

Accepted Answer

Insurance and Medicare Coverage

Most private insurance plans, Medicare Part D, and Medicaid cover Descovy for both HIV treatment and PrEP (pre-exposure prophylaxis). However, the specific copay or coinsurance amount depends on the individual plan's formulary. Some insurers may require prior authorization or a medical necessity form from a healthcare provider before they will cover the medication, especially if generic alternatives are available for the same indication.

Financial Assistance Programs

The manufacturer offers several programs to help reduce the cost of Descovy for eligible patients:

Copay Coupons: For individuals with commercial or private insurance, manufacturer copay cards may reduce out-of-pocket costs to as little as zero dollars per month, up to a specific annual limit.

Patient Assistance Programs: Programs such as Gilead Advancing Access provide the medication at no cost to individuals who are uninsured or underinsured and meet specific income and residency requirements.

Generic Availability

There is currently no generic version of Descovy available in the United States. The medication is protected by patents, which prevents other companies from producing lower-cost generic equivalents at this time. This lack of competition contributes to the higher retail price of the drug compared to older HIV medications that have generic versions.

PrEP Coverage Requirements

Under the Affordable Care Act, many private health insurance plans are required to cover HIV prevention services, including PrEP, without cost-sharing. While this often applies to generic medications, some plans may also cover Descovy without a copay if a healthcare provider determines it is medically necessary for the patient. Patients should check with their insurance provider to understand how Descovy is classified under their specific prevention benefits.

Descovy

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?